Abstract:Objective To determine the population pharmacokinetics of valproic acid(VPA) and identify the factors that explained PK variability in Chinese epileptic children.Methods 390 steady-state serum concentration samples were collected totally.The plasma samples for VPA concentration were analyzed using automated fluorescence polarization method(FPIA) with monoclonal antibodies.In total,321 patients aged 1.8(0.1-13.6) years and weighted 11.5(2.6-84) kg with 390 trough concentrations were extracted.Total body weight,VPA daily dose,gender and comedication with clonazepam,topiramate,carbamazepine,phenobarbital and oxcarbazepine were considered as covariates.A decrease of OFV(from basic model to covariate model) by more than 6.63 was considered to be statistically significant(P0.01,df=1).An increase of OFV from the full model of at least 10.83(P0.001,df = 1) was used as the chosen criterion for retaining the covariate in the model.Pharmacokinetic modeling was performed using NONMEM program(version 6,level 1.1) complied with G77 Fortran.A one-compartment pharmacokinetic model with first-order absorption and elimination(subroutine ADVAN2 and TRANS2) was used to describe the concentration-time data.The first-order conditional estimation method with η-e interaction(FOCE-I) was used throughout the model-building procedure.Various statistical models describing the random residual variability were considered.The reliability and stability of the population pharmacokinetic model developed was further assessed by a nonparametric bootstrap procedure.During this process,each patient was randomly sampled with replacement from the original data set to form new data set containing the same number of patients as the original data set.Results The final model for VPA apparent clearance(CL/F),including age(years),CLO comedication and liver enzyme inducer(carbamazepine or phenobarbital) covariates with a significant influence on this parameter,was as follows: CL/F=0.223·(Age/1.8)0.353·1.22CLO·1.36LEI,V=13.0·(Total body weight/11.5) where CLO was 1 when co-medicated with clonazepam preparation,otherwise CLO was 0;LEI was 1 when co-medicated with carbamazepine or phenobarbital preparation.The typical values for CL/F and apparent volume of distribution(V/F) were 0.223 L·h-1 and 13.0 L,respectively.Interindividual variability(coefficient of variation) for CL/F was 34.3% for final model and 51.5% for basic model;The residual unexplained variability was 25.6 %.In a single attempt of 200 bootstrap analysis,6(3.0%) runs terminated due to rounding errors and were excluded in the analysis.The parameter(except V/F) estimates from nonparametric bootstrap procedure were comparable and within 5% of the estimates from NONMEM.Conclusions A population pharmacokinetic model was proposed to estimate the individual CL/F for paediatric patients receiving VPA in terms of patient′s age,and concomitant clonazepam,carbamazepine or phenobarbital,in order to establish a prior dosage regimens.

Predictors of valproic acid steady-state serum levels in adult and pediatric psychiatric inpatients: a comparative analysis

Retrospective Analysis of Steady-State Sodium Valproate Plasma Concentrations in Chinese Patients With Bipolar Disorder: Impact of Demographic and Clinical Characteristics

Population Pharmacokinetics of Valproate in Chinese Children with Epilepsy.

Factors associated with subtherapeutic levels of valproic acid in hospitalized patients with epilepsy: A retrospective cohort study

Association of Valproic Acid and Its Main Metabolites Plasma Concentrations with Clinical Outcomes among Epilepsy Patients: A 10-Year Retrospective Study Based on Therapeutic Drug Monitoring

Genetic polymorphisms and valproic acid plasma concentration in children with epilepsy on valproic acid monotherapy

Comparison of Weight-Based Valproic Acid Dosing in Treatment of Mental Illness Among Obese and Nonobese Patients

Population pharmacokinetics of valproic acid in adult Chinese epileptic patients and its application in an individualized dosage regimen

Developing pharmacokinetics–pharmacodynamics model of valproic acid syrup based on prediction of population pharmacokinetics parameter and seizure frequency in Indonesian pediatric epilepsy outpatients

Establishment of Population Phamacokinetic Model of Valproic Acid in Chinese Epileptic Children

Determination of the Optimal Concentration of Valproic Acid in Patients with Epilepsy: A Population Pharmacokinetic-Pharmacodynamic Analysis

A randomized controlled trial of initial Valproic acid dosage in epileptic children

Pre-treatment risk predictors of valproic acid-induced dyslipidemia in pediatric patients with epilepsy

Valproic Acid Influences MTNR1A Intracellular Trafficking and Signaling in a β-Arrestin 2-Dependent Manner

Genetic and Non-genetic Factors Contributing to the Significant Variation in the Plasma Trough Concentration-to-Dose Ratio of Valproic Acid in Children With Epilepsy

A review of valproate in psychiatric practice

Physiologically-Based Pharmacokinetic Modeling of Total and Unbound Valproic Acid to Evaluate Dosing in Children With and Without Hypoalbuminemia

Therapeutic and Toxic Effects of Valproic Acid Metabolites

Factors Influencing Plasma Concentrations of Valproic Acid in Pediatric Patients with Epilepsy and the Clinical Significance of CYP2C9 Genotypes in Personalized Valproic Acid Therapy

Population pharmacokinetics of valproic acid in children with epilepsy: Implications for dose tailoring when switching from oral syrup to sustained‐release tablets

An ID-HPLC–MS/MS based candidate reference measurement procedure for the quantification of valproic acid in human serum